liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD
Linköping University, Department of Clinical and Experimental Medicine. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Heart and Medicine Center, Department of Nephrology. Karolinska Institute, Sweden.
RWTH University Hospital Aachen, Germany.
University of Calif Irvine, CA 92868 USA; University of Calif Los Angeles, CA 90502 USA.
Karolinska Institute, Sweden.
Show others and affiliations
2017 (English)In: Nature Reviews Nephrology, ISSN 1759-5061, E-ISSN 1759-507X, Vol. 13, no 7, 429-442 p.Article, review/survey (Refereed) Published
Abstract [en]

Cardiovascular disease is the main cause of early death in the settings of chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), and ageing. Cardiovascular events can be caused by an imbalance between promoters and inhibitors of mineralization, which leads to vascular calcification. This process is akin to skeletal mineralization, which is carefully regulated and in which isozymes of alkaline phosphatase (ALP) have a crucial role. Four genes encode ALP isozymes in humans. Intestinal, placental and germ cell ALPs are tissue-specific, whereas the tissue-nonspecific isozyme of ALP (TNALP) is present in several tissues, including bone, liver and kidney. TNALP has a pivotal role in bone calcification. Experimental overexpression of TNALP in the vasculature is sufficient to induce vascular calcification, cardiac hypertrophy and premature death, mimicking the cardiovascular phenotype often found in CKD and T2DM. Intestinal ALP contributes to the gut mucosal defence and intestinal and liver ALPs might contribute to the acute inflammatory response to endogenous or pathogenic stimuli. Here we review novel mechanisms that link ALP to vascular calcification, inflammation, and endothelial dysfunction in kidney and cardiovascular diseases. We also discuss new drugs that target ALP, which have the potential to improve cardiovascular outcomes without inhibiting skeletal mineralization.

Place, publisher, year, edition, pages
NATURE PUBLISHING GROUP , 2017. Vol. 13, no 7, 429-442 p.
National Category
Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:liu:diva-138880DOI: 10.1038/nrneph.2017.60ISI: 000403368800015PubMedID: 28502983OAI: oai:DiVA.org:liu-138880DiVA: diva2:1115958
Available from: 2017-06-27 Created: 2017-06-27 Last updated: 2017-06-27

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Haarhaus, MathiasMagnusson, Per
By organisation
Department of Clinical and Experimental MedicineFaculty of Medicine and Health SciencesDepartment of NephrologyDivision of Microbiology and Molecular MedicineDepartment of Clinical Chemistry
In the same journal
Nature Reviews Nephrology
Endocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 52 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf